Welcome to Markets Desk, here's what's moving markets this afternoon.
Salesforce made a bold move last week, announcing a three point six billion dollar acquisition aimed squarely at defending its turf against the so-called SaaSpocalypse — the threat that AI tools will erode demand for traditional software subscriptions. If the bet pays off, analysts say shares look deeply undervalued at current levels.
Shifting to insider activity, a director at Ryan Specialty Holdings, Anthony Kuczinski, purchased three thousand shares across June eleventh and twelfth, paying a weighted average of roughly thirty four dollars and ninety nine cents per share — a total outlay of around one hundred five thousand dollars. Insider buying at that scale tends to signal conviction that the stock has room to run.
And in healthcare, a landmark shift takes effect July first, as Medicare begins covering obesity drugs for seniors — a massive expansion that could reshape the GLP-one market. Despite the significance, both the government and drugmakers Eli Lilly and Novo Nordisk have done remarkably little to advertise the change, leaving many eligible beneficiaries unaware they now have access to coverage.
That's the tape. Markets Desk, signing off the floor.
